Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 187

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 187
---
2 million in fiscal 2022; • Net Loss attributable to Arrowhead Pharmaceuticals, Inc. — Recorded net loss of $599.5 million, compared to net losses of $205.3 million in fiscal 2023 and $176.1 million in fiscal 2022; • Net Loss Per Share attributable to Arrowhead Pharmaceuticals, Inc. — Recorded net loss per share (diluted) of ($5.00), compared to net loss per share (diluted) of ($1.92) in fiscal 2023 and ($1.67) in fiscal 2022; • Cash at end of fiscal 2024 — Cash and investments of cash totaled $681.0 million at September 30, 2024; and • Total Stockholder Return — Achieved a three-year total stockholder return (“TSR”) at the 28th percentile of our peer group as measured in September 2024. Table of Contents 2025 PROXY STATEMENT Executive Compensation 29

COMPARISON OF CUMULATIVE TOTAL RETURN Arrowhead Pharmaceuticals, Inc. NASDAQ Biotechnology NASDAQ Composite 2019 2020 2021 2022 2023 2024 0 100 200 300 400 The comparisons in the above graph are based on historical data and are not intended to forecast the possible future performance of our common stock. Executive Compensation Highlights Say-on-Pay Vote and Ongoing Response to Stockholder Feedback At our 2024 Annual Meeting of Stockholders, 94% of the stockholder votes cast on our non-binding, advisory proposal (the “Say-on-Pay” vote) on the executive compensation program were in favor of the program. Our Board of Directors was pleased with this result. We value the opinions of our stockholders and will continue to consider the outcome of future Say-on-Pay votes, as well as feedback received throughout the year, when making compensation decisions for our executive officers. The Compensation Committee is committed to being responsive to stockholder feedback regarding our executive compensation program, policies, and practices, including concerns expressed through the Say-on-Pay vote. Stockholder Engagement During the summer and fall of 2023, our Corporate Secretary and Mr. Waddill, the Compensation Committee Chair, requested meetings with our top 10 stockholders to discuss our executive compensation program. On the basis of that feedback, and the stockholder vote during our 2024 Annual Meeting of Stockholders, we believe stockholders are pleased with our current compensation approach. Aggressive